CALiPSO-1, NCT06255028: A Study of CNTY-101 in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE) |
|
|
| Not yet recruiting | 1 | 26 | US | CNTY-101, IL-2, Lymphodepleting Chemotherapy | Century Therapeutics, Inc. | Systemic Lupus Erythematosus | 08/28 | 08/28 | | |
| Recruiting | 1 | 75 | US | CNTY-101, IL-2, Lymphodepleting Chemotherapy | Century Therapeutics, Inc. | R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma | 08/25 | 08/27 | | |